How many patents does
Roche Glycart have?
patents
1,686
families
85
granted
328
applications
1,358
US
213
EP
138
JP
103
CN
100
KR
88
WO
80
RoW
964
Buy the report
The report contains ten-year analysis with the following sections
- patent filing analysis
- worldwide filing analysis
- patent family analysis
- application analysis
- granted analysis
- classification analysis
- citation analysis
contact us for pricing
- VAT will apply to UK companies
- EU companies must supply their VAT number
Check out our sample pages |
Find companies to compare
Many companies now available
companies
12,000+
patents
42 million
patent families
23 million
Search to find companies of interest
read summary of their published patent
the following tables are just extracts from the report
the company report contains more information
Roche Glycart
Top ten assignees appearing on patents
2009 - 2018
| roche glycart | 1218 |
| glycart biotechnology | 142 |
| roche | 69 |
| roche palo alto | 2 |
| roche glyeart | 2 |
| roche glycart a. | 2 |
| roche gycart | 1 |
| glikart bioteknolodzhi | 1 |
| glikart biotekhnologi | 1 |
2009
| glycart biotechnology | 36 |
| roche | 19 |
| roche glycart | 9 |
2018
| roche glycart | 143 |
| roche | 4 |
Roche Glycart
The top ten patent families are
|
Title of patent family (most common patent title) |
Family members |
Filing year |
|---|---|---|
| cd20 antibodies with increased fc receptor binding affinity and effector function | 97 | 2003 |
| mutant interleukin-2 polypeptides | 65 | 2011 |
| anti-fap antibodies and methods of use | 58 | 2010 |
| fusion constructs and use of same to produce antibodies with increased fc receptor bindi… 🛈 | 57 | 2003 |
| cea antibodies | 47 | 2011 |
| anti-her3 antibodies and uses thereof | 46 | 2009 |
| combination therapy of an afucosylated cd20 antibody with bendamustine | 46 | 2009 |
| combination therapy of a type ii anti-cd20 antibody with increased antibody dependent ce… 🛈 | 45 | 2008 |
| bispecific t cell activating antigen binding molecules | 43 | 2011 |
| glycosylation engineering of antibodies for improving antibody-dependent cellular cytoto… 🛈 | 42 | 1998 |